Leerink Partners analyst Puneet Souda has maintained their bullish stance on OABI stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Puneet Souda has given his Buy rating due to a combination of factors that highlight OmniAb’s strategic positioning and financial health. The company is recognized as a unique provider in the antibody therapeutics sector, with a scalable business model that supports growth in partner programs. Despite modest net program additions in the second quarter of 2025, the underlying program starts remain robust, indicating a healthy pipeline. Additionally, OmniAb’s management has implemented cost-saving measures, including headcount reductions, which are expected to result in significant annual savings by 2026.
Another factor contributing to the Buy rating is the successful launch of OmniAb’s xPloration platform, which has already attracted interest from potential customers and generated revenue shortly after its introduction. The company’s financial stability is further underscored by a strong cash position and improved deal economics, as evidenced by an increased average royalty rate. With a growing pipeline of post-discovery programs and a lean operating model, OmniAb is well-positioned to manage its cash balance effectively as its pipeline matures.
Souda covers the Healthcare sector, focusing on stocks such as Illumina, Quanterix, and 908 Devices. According to TipRanks, Souda has an average return of -9.8% and a 31.65% success rate on recommended stocks.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $3.00 price target.